Welcome to our dedicated page for RESEARCH ALLIANCE III SEC filings (Ticker: RACC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on RESEARCH ALLIANCE III's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into RESEARCH ALLIANCE III's regulatory disclosures and financial reporting.
Research Alliance Corp III reported institutional ownership disclosures by Biotechnology Value Fund entities as of May 29, 2026. The filing states Biotechnology Value Fund, L.P. beneficially owned 261,923 shares (approximately 3.4%); Biotechnology Value Fund II, L.P. owned 197,667 shares (approximately 2.5%); and Biotechnology Value Trading Fund OS LP owned 33,116 shares (less than 1%).
The schedule aggregates related holdings and reports that certain related entities may be deemed to beneficially own larger amounts: BVF GP Holdings LLC may be deemed to beneficially own 459,590 shares (approximately 5.9%), and Partners, BVF Inc., and Mark N. Lampert may be deemed to beneficially own 500,000 shares (approximately 6.4%). The percentages are calculated using 7,775,000 Shares outstanding reported as of the issuer's underwritten public offering May 20, 2026.
Research Alliance Holdings III LLC and Matthew Hammond report a 14.7% stake in Research Alliance Corporation III’s Class A ordinary shares. They beneficially own 1,520,269 Class A shares on an as-converted basis, including Class B founder shares that convert one-for-one into Class A upon the SPAC’s business combination.
The sponsor paid $25,000 for 1,014,706 initial Class B shares and later held 1,245,269 Class B shares after a share capitalization, plus 275,000 Class A shares bought in a private placement at $10.00 per share for $2,750,000. These holdings are subject to lock-up, voting, registration rights, and board nomination arrangements tied to the SPAC’s initial business combination.
Research Alliance Corporation III disclosure: Trails Edge entities and Ortav Yehudai report beneficial ownership of 500,000 Class A Ordinary Shares, representing 5.5% of the outstanding shares as of May 21, 2026. Ownership is based on 9,098,529 Ordinary Shares outstanding as of May 20, 2026, with the shares held directly by Trails Edge Biotechnology and voting/investment discretion exercised by Trails Edge Capital and Mr. Yehudai.
Research Alliance Corporation III completed its initial public offering of 7,500,000 Class A ordinary shares at $10.00 per share, raising $75,000,000 in gross proceeds. A concurrent private placement of 275,000 Class A shares added $2,750,000. In total, $75,000,000 was placed into a segregated trust account for the benefit of public shareholders, while $1,255,049 of cash remained available for working capital. The audited balance sheet shows Class A shares subject to possible redemption of 7,500,000 shares at $10.00 each and a shareholders’ deficit of about $1.1 million, typical for a newly formed blank check company before a business combination.
Research Alliance Corp III reports a Schedule 13G filing showing an aggregate 500,000 shares of Class A Ordinary Shares beneficially owned by Commodore Capital entities and two managing partners as of May 20, 2026.
Ownership represents 5.5% of the issuer's Common Shares based on 9,098,529 shares outstanding as of May 19, 2026 reported in the issuer's Rule 424(b)(4) Prospectus Supplement. The filing states shared voting and dispositive power for the 500,000 shares among Commodore Capital LP, Commodore Capital Master LP, Robert Egen Atkinson, and Michael Kramarz.
Research Alliance Corporation III reports that Perceptive Advisors, Joseph Edelman and Perceptive Life Sciences Master Fund, Ltd. each beneficially own 750,000 Class A Ordinary Shares. The filing states this equals 8.2% of the class based on 9,098,529 Ordinary Shares outstanding as reported in the Issuer's prospectus dated 05/20/2026.
The filing shows shared voting and shared dispositive power over the 750,000 shares for each Reporting Person and attributes beneficial ownership to Perceptive Advisors and Mr. Edelman by virtue of managerial and investment‑management relationships.
Research Alliance Holdings III LLC /Cayman reported acquisition or exercise transactions in this Form 4 filing.
Research Alliance Holdings III LLC /Cayman, a director and ten percent owner of Research Alliance Corp III, received a grant of 275,000 Class A Ordinary Shares on May 21, 2026. The shares were valued at $10.00 per share, and the LLC held 275,000 shares directly after this award.
Research Alliance Corp III director and CEO Matthew Hammond reported an acquisition of 275,000 Class A Ordinary Shares at $10.00 per share. The shares are held indirectly through Research Alliance Holdings III LLC, the sponsor entity, which now holds 275,000 shares after this grant or award.
Hammond is the sole director of the sponsor and has voting and investment discretion over these securities, but he disclaims beneficial ownership except for any pecuniary interest he may have. This is a compensation-related acquisition rather than an open-market purchase.
Research Alliance Corporation III, a healthcare-focused special purpose acquisition company, completed its initial public offering of 7,500,000 Class A ordinary shares at $10.00 per share, raising gross proceeds of $75,000,000.
The company also completed a private placement of 275,000 Class A shares to its sponsor at $10.00 per share for $2,750,000. As of May 21, 2026, $75,000,000 of IPO and private placement net proceeds, including a $2,250,000 deferred underwriting commission, were placed in a trust account for the benefit of public shareholders.
In connection with the IPO, Michael F. MacLean and Timothy J. Miller joined the board and its key committees, each holding 39,130 Class B founder shares after a share transfer and capitalization. The company adopted amended constitutional documents and listed its Class A shares on the Nasdaq Capital Market under the symbol RACC.
Research Alliance Corporation III is a newly formed Cayman Islands blank check company conducting an initial public offering of 7,500,000 Class A ordinary shares at $10.00 per share for aggregate gross proceeds of $75,000,000. The proceeds (less permitted interest withdrawals and underwriting items) will be held in a U.S. trust account for use in an initial business combination.
The sponsor purchased founder shares for an aggregate $25,000 and will purchase 275,000 private placement shares at closing for $2,750,000. Public shareholders can redeem shares at the trust-account per-share amount upon a business combination; the company must complete a business combination within 24 months or liquidate. The founder shares will convert into Class A on a one-for-one basis (subject to anti-dilution) and are structured to equal an aggregate 15% as-converted ownership, which the prospectus shows can produce immediate dilution to public investors.